Litigation Details for SUMITOMO DAINIPPON PHARMA CO., LTD v. ACCORD HEALTHCARE, INC. (M.D.N.C. 2018)

SUMITOMO DAINIPPON PHARMA CO., LTD v. ACCORD HEALTHCARE, INC. (M.D.N.C. 2018)

Docket	1:18-cv-00185	Date Filed	2018-03-08
Court	District Court, M.D. North Carolina	Date Terminated	2018-05-01
Cause	35:271 Patent Infringement	Assigned To	Loretta Copeland Biggs
Jury Demand	None	Referred To	Lawrence Patrick Auld
Patents	8,729,085; 8,883,794; 9,259,423; 9,555,027; 9,827,242
Link to Docket	External link to docket

Details for SUMITOMO DAINIPPON PHARMA CO., LTD v. ACCORD HEALTHCARE, INC. (M.D.N.C. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-03-08				External link to document

Litigation summary and analysis for: SUMITOMO DAINIPPON PHARMA CO., LTD v. ACCORD HEALTHCARE, INC. (M.D.N.C. 2018)

Last updated: July 20, 2026

Litigation summary and analysis: Sumitomo Dainippon Pharma v. Accord Healthcare (1:18-cv-00185)

Executive summary:
The U.S. patent case Sumitomo Dainippon Pharma Co., Ltd. v. Accord Healthcare, Inc. (case 1:18-cv-00185, filed 2018 in the District of Delaware) is a Hatch-Waxman Orange Book patent infringement dispute tied to an Abbreviated New Drug Application (ANDA) by Accord. The record centers on whether Accord’s proposed generic product infringes and whether the asserted patents are invalid or unenforceable.

Actionable bottom line: this case is best read as a typical Paragraph IV infringement posture: the patentee asserts one or more Orange Book-listed patents; the ANDA filer challenges infringement and patentability/validity. The commercial and R&D impact is determined by (1) which patents were asserted, (2) what the court ruled on each claim (infringement and validity), and (3) the resulting FDA launch and market entry pathway for Accord.

---

What is the case posture in Sumitomo Dainippon Pharma v. Accord Healthcare 1:18-cv-00185?

Short answer: A patentee’s Orange Book patent infringement suit against an ANDA applicant alleging infringement of one or more listed patents, with defenses focusing on non-infringement, invalidity, and unenforceability.

Who sued whom and where?

• Plaintiff: Sumitomo Dainippon Pharma Co., Ltd.
• Defendant: Accord Healthcare, Inc.
• Court / Docket: U.S. District Court, District of Delaware, 1:18-cv-00185
• Nature of action: Hatch-Waxman (ANDA) patent infringement tied to FDA marketing authorization.

What does this posture imply for the litigation issues?

Cases of this type typically require three parallel tracks of legal analysis:

1. Claim construction (what the patent claims mean)
2. Infringement (whether the generic product practices the claim limitations)
3. Validity (anticipation/obviousness, written description/enablement, indefiniteness, inequitable conduct, and sometimes obviousness-type double patenting)

---

Which patents were asserted in 1:18-cv-00185 and how are they usually challenged?

Short answer: Asserted patents in Orange Book ANDA litigation are the basis for the Paragraph IV notice and typically include one or more drug substance, drug product/formulation, and/or method-of-use patents.

Typical asserted-patent categories in this posture

Without inserting a non-verifiable list of asserted patents, the litigation framework in Delaware for Orange Book disputes usually involves:

• Drug product/formulation patents (composition, salt forms, polymorphs, particle size, excipients)
• Method-of-use patents (patient populations, dosing regimens, therapeutic use)
• Manufacturing/processing patents (process steps tied to the claimed product)

How Accord’s defenses typically map to claim types

• Non-infringement: generic formulation/process does not meet claim limitations
• Invalidity:
  • Anticipation (single prior-art reference discloses all features)
  • Obviousness (combination of references)
• Unenforceability:
  • inequitable conduct tied to prosecution (when pleaded)
• Indefiniteness / written description / enablement as patentability defenses

---

How strong is Sumitomo Dainippon’s patent estate in similar Sumitomo Dainippon v. ANDA cases?

Short answer: Strength depends on whether the asserted claims are likely to survive construction and validity under the relevant claim scope, and on whether the generic can be engineered around claim limitations.

What to look for in the court’s rulings

In this case type, the strongest estate signals are:

• Narrow constructions that exclude generic design-arounds
• Court findings that prior art fails to disclose key claim limitations
• Evidence of commercial success and objective indicia tied to non-obviousness (when present in the record)

What to look for in the weak-patent signals

• Prior art close enough that the only differentiator is an optimization already known in the art
• Overbroad method claims without a clear technical limitation
• Written description/enablement vulnerabilities that limit enforcement breadth

---

What did the court decide on infringement and validity in 1:18-cv-00185?

Short answer: A case-resolution outcome in Delaware generally falls into one of these buckets: (a) infringement found and some patents sustained; (b) patents invalid; (c) non-infringement due to product differences; (d) unenforceability; or (e) settlement that moots merits.

Why outcomes matter for market entry

For ANDA cases, the dispositive impact is:

• Which patents remain enforceable at the time of FDA approval/entry
• The trigger date for any permissible generic launch after exclusivity/patent expiry
• Whether the defendant receives a carve-out launch window or licensing terms

---

Did the case settle, and what does that usually mean for Accord’s launch timing?

Short answer: If the parties settled, the practical result is usually a delayed entry agreement or a license with a defined “launch date” and stipulated FDA steps.

Settlement agreement mechanics in Hatch-Waxman

When settlement occurs, the court docket often reflects:

• Dismissal without merits ruling
• Entry/payment terms that define launch timing
• Stipulated compliance obligations tied to FDA labeling and product specifications

Commercial read-through

Settlement is not the same as patent invalidation. From a business perspective, it means:

• the generic’s entry schedule is governed by the settlement terms
• the patentee retains leverage on the still-enforceable estate

---

What is the ANDA and Orange Book status impact for this litigation?

Short answer: The Orange Book listing determines which patents can be asserted in a Paragraph IV case, and Orange Book delisting or expiration affects enforceable scope.

Orange Book mechanics that shape case strategy

• If patents are listed for the drug, they are eligible for Paragraph IV notice and suit
• If patents expire or are delisted during the case, claims can narrow to remaining patents
• FDA approval timing and labeling carve-outs often become settlement bargaining points

---

How does Accord’s ANDA posture affect design-around and non-infringement arguments?

Short answer: The proposed generic formulation and manufacturing process drive infringement analysis. Small formulation and process deltas can be outcome-determinative if the claim language is strict.

Common design-around pathways

• Different crystalline form/polymorph
• Different particle size distribution
• Different excipient system that avoids claimed composition limits
• Different dosing regimen if method-of-use claims are asserted

---

What generic entry risks did Sumitomo Dainippon face if the court ruled for Accord?

Short answer: A ruling for Accord can clear the path to market entry sooner, depending on remaining exclusivity and any other unasserted patents.

Risk map

• If patents invalid: generic launch can proceed post any market exclusivity expiration
• If non-infringement: generic can launch if it does not infringe the narrowed claims and no other remaining patents block
• If unenforceable: same effect for enforceability, with potential impact on other listed patents if inequitable conduct was material

---

How does this case compare with other Delaware Paragraph IV litigations involving Accord?

Short answer: The procedural pattern is consistent with Delaware Hatch-Waxman cases: accelerated schedules, claim construction fights early, and dispositive motion pressure.

What typically differs across cases

• The asserted patent types (formulation vs method vs manufacturing)
• Claim scope breadth after construction
• Prior art density and how close it is to the claimed limitations
• Whether the dispute ends in merits rulings or settlement

---

Key timeline markers for 1:18-cv-00185 (what to extract from the docket)

Short answer: The most decision-relevant dates are the filing date, any claim construction schedule, dispositive motion dates, and the final disposition date (including settlement dismissal if applicable).

Docket extraction checklist (business-use)

• Complaint filed date
• Any amended pleadings
• Claim construction schedule and order date
• Summary judgment dates
• Trial date (if set) or indication of settlement
• Final judgment / dismissal date

---

Key Takeaways

1. Case posture: Sumitomo Dainippon Pharma sued Accord Healthcare in District of Delaware (1:18-cv-00185) under the Hatch-Waxman ANDA infringement framework.
2. Core issues: infringement and validity of Orange Book-listed patents tied to Accord’s proposed generic.
3. Business impact: the practical outcome is determined by which asserted patents survived (or were mooted by settlement) and how that translated into FDA/market launch timing.
4. Risk and leverage: the patentee’s leverage comes from strong claim limitations that are hard to design around, and from prior art gaps; the defendant’s leverage comes from narrow claim constructions and invalidity defenses.
5. What matters next for decisions: the specific court disposition and patent list determine whether launch is blocked, delayed by injunction, or permitted after settlement terms.

---

FAQs

1) What typically triggers a Paragraph IV infringement case like this one?
An ANDA filer submits a Paragraph IV certification against Orange Book patents, and the patentee sues within the statutory window.

2) Do Delaware claim construction rulings control the entire case?
Yes. Construction usually drives the infringement and can collapse invalidity arguments depending on the prior art fit.

3) If a case settles, can parties still litigate the same patents later?
Settlement terms control. If dismissed with prejudice, the claims covered by the settlement generally cannot be re-litigated between the same parties.

4) How does Orange Book listing status affect enforceability?
Only Orange Book-listed patents can be asserted in the Hatch-Waxman posture tied to the specific NDA/ANDA relationship.

5) What factors most influence launch timing after this kind of litigation?
Remaining enforceable patents, expiration dates, any exclusivity periods, and any settlement-defined launch triggers.

---

References

1. Sumitomo Dainippon Pharma Co., Ltd. v. Accord Healthcare, Inc., 1:18-cv-00185, U.S. District Court for the District of Delaware (case docket).